GI Dynamics Terminates Pivotal Endobarrier Trial Based On Safety Data
This article was originally published in The Gray Sheet
Executive Summary
FDA and the company could not come up with a plan to continue the ENDO study for GI's device targeting obese patients with diabetes in response to higher-than-anticipated rates of liver infection. The company suggests, however, that development of the device will continue.
You may also be interested in...
ReShape Dual Balloon Enters U.S. Market, Headlining Week Of Obesity Device News
It was a banner day for minimally invasive weight-loss devices July 28. FDA approved ReShape Medical's intragastric balloon and Aspire Bariatrics submitted an application for its AspireAssist aspiration therapy system for obesity. Two days later, GI Dynamics announced the termination of a pivotal study for its Endobarrier device.
ReShape Dual Balloon Enters U.S. Market, Headlining Week Of Obesity Device News
It was a banner day for minimally invasive weight-loss devices July 28. FDA approved ReShape Medical's intragastric balloon and, on the same day, Aspire Bariatrics reached a key milestone with the PMA submission for its AspireAssist aspiration therapy system for obesity. Two days later, GI Dynamics announced the termination of a pivotal study for its Endobarrier device.
GI Dynamics Goes Down Under To Fund First Endoscopic Treatment For Diabetes
The Massachusetts-based developer of the EndoBarrier device is leveraging its presence on the Australian stock exchange to finance its drug-like clinical development changes.